Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase II Clinical Trial of ATH-1017 for the Treatment of Parkinson’s Disease Dementia and Dementia with Lewy Bodies

Athira Pharma, Inc. announced that patient dosing has begun in SHAPE, a Phase II clinical trial of ATH-1017 for the treatment of Parkinson’s disease dementia and Dementia with Lewy bodies. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.